Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro.
about
Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adultsPromising functional readouts of immunity in a blood-stage malaria vaccine trialMerozoite surface proteins in red blood cell invasion, immunity and vaccines against malariaPlasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding proteinT cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccinesPlasmodium falciparum merozoite surface protein 8 is a ring-stage membrane protein that localizes to the parasitophorous vacuole of infected erythrocytes.Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malariaProduction of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparumLong-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections.Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.Construction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9.The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection.In vitro growth-inhibitory activity and malaria risk in a cohort study in maliAllele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.Schistosomiasis coinfection in children influences acquired immune response against Plasmodium falciparum malaria antigensPlasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assaysFunctional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells.Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.Specificity of the protective antibody response to apical membrane antigen 1Complement contributes to protective immunity against reinfection by Plasmodium chabaudi chabaudi parasites.Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodiesFine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection.Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoitesTowards a blood-stage vaccine for malaria: are we following all the leads?Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of responseAntibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines.Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodiesPhase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.The immunological challenge to developing a vaccine to the blood stages of malaria parasites.Polymorphisms in B Cell Co-Stimulatory Genes Are Associated with IgG Antibody Responses against Blood-Stage Proteins of Plasmodium vivax.Plasmodium falciparum line-dependent association of in vitro growth-inhibitory activity and risk of malaria.
P2860
Q21144326-3C1CBD3A-F31A-4F4C-A71A-BFB9B73B617AQ24814446-5D3A2B23-BFDC-496A-9F7D-66829FCD298BQ26772878-40D8949C-B14C-40B0-9EC4-EC09341A6202Q28471832-E8AC0A91-DDB4-464D-A98E-9C37499C5477Q28740432-9A70BF7B-0D7D-4A25-850F-7B2E4805C7DFQ30043111-87967447-B500-49BF-9EF0-223CAE224836Q33264521-113EC522-C8E5-4F2D-A70A-DCEC254C95CEQ33281394-CD227741-72E0-4EF8-91EB-ABE7B674B06AQ33282524-15F7FD37-6CF3-4FDC-A86E-41E3B664B2D8Q33305467-DBC1802C-CDA7-4FFD-B162-A6CFAB01929CQ33362115-E43EAC82-5C36-409A-93A5-D31FED0E556FQ33380204-052E3A19-753E-4B3E-9046-5BBC5F7EA99EQ33499694-2DFD0B1B-8255-4F49-A41C-0DD5C30056C6Q33526349-1B917B95-C193-48C9-969F-B0C46DA7366FQ33558061-99F6374F-57FC-4C1E-B3D3-80C159ED80E6Q33613813-A9E3E57C-B90A-4A06-BFD3-D3CAF8FA7608Q33613892-A2785E86-4EA3-4B0A-A454-D518D987FE36Q33653151-544AA7B9-17CC-48C4-8A8E-B0FC07D58A74Q33697651-B55F75D3-7CC2-420E-BC72-8248E2424AABQ33742070-BDB972BD-4B64-49C2-AB51-66DF246E1B37Q33939788-8F5CD371-5A2B-4169-BC9E-06BFDF981605Q33957155-A2E119F8-E54D-4213-9DA5-7CA0F391F491Q34003578-1E6E028F-ACAB-4D31-8C79-9BC61596B4D9Q34007362-5D972E91-62DD-4A6A-84FF-738D5E4138EEQ34007833-94A06903-519D-4812-A4FA-D967E5B7F234Q34081745-72E0DD41-9F70-407E-B758-3B76B2191C5EQ34131183-5A69D73E-750C-4E09-8C12-B6A98C739A6EQ34249359-65FD8E95-FCD7-4F9D-B450-C4FF0845EC0DQ34540211-7638EFA6-9EB1-4B44-A22E-AF9BDB973D50Q34572160-5993575F-F1D4-489C-8228-9B23D5F7E7CCQ34955461-22938890-6739-45D9-99FC-CD1BF3A39AF1Q35010158-9043042D-3942-4680-B3CF-F99B20C9195BQ35212980-C69F5D49-3431-4719-99F4-80CAC806CD7EQ35241288-144A17F8-ADDB-4820-9855-CC68282A0FD3Q35456892-6B4F1BF3-C587-4FB3-8ABD-F9B1C0360137Q35557657-F0A69F43-FB7A-458B-B360-CAFA2CF0F5EBQ35762375-27031F28-BFDC-4DF8-A90A-613AB7F28E99Q35884247-7F4C33EE-8280-4954-A8D1-69440E9EDBBEQ35931132-BFE2DC0C-51E7-4131-A7B2-BFB87E649353Q35944117-2F36F4CD-EB56-4ECE-8B31-54F3A01BD644
P2860
Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@en
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@nl
type
label
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@en
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@nl
prefLabel
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@en
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@nl
P2093
P2860
P1433
P1476
Human antibodies to the 19kDa ...... ibit parasite growth in vitro.
@en
P2093
P2860
P304
P356
10.1046/J.1365-3024.1999.00209.X
P577
1999-03-01T00:00:00Z